UCLA researchers find promising results in a two-drug therapy for methamphetamine use disorder, with a 27% increase in drug-free urine tests in the ADAPT-2 trial.

UCLA researchers report promising results from a two-drug therapy for methamphetamine use disorder, consisting of injectable naltrexone and extended-release oral buproprion. In the ADAPT-2 clinical trial, participants receiving the combination experienced a 27% increase in drug-free urine tests, compared to an 11% increase in a control group. The study will continue to investigate the treatment's long-term effects and optimal duration.

June 10, 2024
8 Articles

Further Reading